LLS Phone Education Program: "Managing Myeloma"
On October 29, as part of the Leukemia & Lymphoma Society's ongoing Lymphoma Education Series, the LLS is offering another FREE telephone education program.
In order to participate, you need only to register. These are free, 90 minute programs hosted by blood cancer experts and followed by Q&A sessions in which you can ask questions. You don't need to go anywhere to participate, you don't need to pay anything, you just need to call in at the proper time.
Program: Managing Myeloma: An Expert's Update
About: Learn about signs, symptoms, emerging treatment options, how treatments are selected for patients, and clinical trials for myeloma.
When: October 29, 2009 at 12 noon (eastern time)
Hosted by:
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine, Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA
Click HERE for the program's main information page, and to access the registration page.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
